Studies related to Bone Fracture Risk and Vitamin K

Three-year Low-dose Menaquinone-7 Supplementation Helps Decrease Bone Loss In Healthy Postmenopausal Women

Effect Decrease
Trial Design Double blind
Trial Length 6+ Months
Number of Subjects 223
Sex Female
Age Range 45-64, 65+
Body Types Overweight
Notes for this study:
180μg of MK-7 daily for a period of three years in otherwise healthy postmenopausal women was able to increase circulating carboxylated osteocalcin (21+/-19% increase seen with MK-7 and none in placebo) and decreased the uncarboxylated osteocalcin (51+/-21%) within one year (maintained for two years) which was associated with a preservation of femoral and spine bone mineral density (no influence on hip) and increase in bone strength, there were less fractures associated with MK-7 relative to placebo.
Funding issues for this study:
Funded by Nattopharma, producer of the MK-7 capsules used; no conflict of interest apparent

Full details on all 2 studies are available to Examine Members. Try out the Examine Membership with a 14-day free trial.

Already a Member? Log in now to access.